Clinical study of Tongren Wuji Baifeng Pill in the treatment of hyperuricemia in patients with chronic kidney disease
- Conditions
- Chronic kidney disease with hyperuricemia
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Age 18-70 years old, regardless of gender
(2) Patients meeting the diagnostic criteria for CKD and staged as CKD stage 2-4 (15 ml/min.1.73m2=GFR<90 ml/min.1.73m2)
(3) Meeting the diagnostic criteria of hyperuricemia
(4) Patients with evidence of spleen and kidney deficiency and blood deficiency with stasis
(5) Signed informed consent form
(1) Taking one or more of the Western medicine uric acid-lowering drugs, such as allopurinol, benzbromarone, probenecid, febuxostat, etc. within the last 1 month
(2) Uncontrollable hypertension/hypotension: systolic blood pressure = 200 mmHg or diastolic blood pressure = 110 mmHg; or systolic blood pressure = 90 mmHg or diastolic blood pressure = 60 mmHg
(3) Change in blood creatinine level of more than 50% in the last 3 months
(4) Combination of various acute infections, or with severe infections, severe anaemia, etc.
(5) History or complications of malignancy
(6) Organic heart disease, such as congenital heart disease, rheumatic heart disease, etc.
(7) Severe liver function abnormalities (ALT or AST greater than 3 times the upper limit of normal)
(8) Pregnant or lactating women
(9) Participating in any other clinical trial
(10) Any other reason why the investigator considers it inappropriate to participate in this study
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method